{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T18:18:33Z","timestamp":1791224313972,"version":"4.1.0"},"reference-count":26,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2011,1,1]],"date-time":"2011-01-01T00:00:00Z","timestamp":1293840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nuclear Medicine and Biology"],"published-print":{"date-parts":[[2011,1]]},"DOI":"10.1016\/j.nucmedbio.2010.06.010","type":"journal-article","created":{"date-parts":[[2010,9,2]],"date-time":"2010-09-02T08:55:41Z","timestamp":1283417741000},"page":"129-136","source":"Crossref","is-referenced-by-count":22,"title":["A kit to prepare 111In-DTPA-trastuzumab (Herceptin) Fab fragments injection under GMP conditions for imaging or radioimmunoguided surgery of HER2-positive breast cancer"],"prefix":"10.1016","volume":"38","author":[{"given":"Deborah A.","family":"Scollard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Conrad","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire M.B.","family":"Holloway","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond M.","family":"Reilly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nucmedbio.2010.06.010_bb0005","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/S0959-8049(97)10157-5","article-title":"ERBB2 oncogene in human breast cancer and its clinical significance","volume":"34","author":"Revillion","year":"1998","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.nucmedbio.2010.06.010_bb0010","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/0046-8177(92)90257-4","article-title":"Overexpression of HER-2\/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer","volume":"23","author":"Allred","year":"1992","journal-title":"Hum Pathol"},{"key":"10.1016\/j.nucmedbio.2010.06.010_bb0015","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1023\/A:1006111117877","article-title":"HER-2\/neu as a predictive marker of response to breast cancer therapy","volume":"52","author":"Pegram","year":"1998","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.nucmedbio.2010.06.010_bb0020","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1126\/science.3798106","article-title":"Human breast cancer: correlation of relapse and survival with amplification of the HER-2\/neu oncogene","volume":"235","author":"Slamon","year":"1987","journal-title":"Science"},{"key":"10.1016\/j.nucmedbio.2010.06.010_bb0025","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1038\/sj.clpt.6100096","article-title":"Molecular imaging as a tool for personalized and targeted anticancer therapy","volume":"81","author":"McLarty","year":"2007","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.nucmedbio.2010.06.010_bb0030","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.2967\/jnumed.108.060772","article-title":"Aiming for a direct hit: combining molecular imaging with targeted cancer therapy","volume":"50","author":"Reilly","year":"2009","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2010.06.010_bb0035","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1002\/(SICI)1098-2388(199812)15:4<245::AID-SSU12>3.0.CO;2-2","article-title":"Use of radioimmunoguided surgery after induction chemotherapy in locally advanced breast cancer","volume":"15","author":"Badellino","year":"1998","journal-title":"Semin Surg Oncol"},{"key":"10.1016\/j.nucmedbio.2010.06.010_bb0040","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1200\/JCO.1996.14.5.1599","article-title":"Radioimmunoguided surgery after primary treatment of locally advanced breast cancer","volume":"14","author":"Percivale","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.nucmedbio.2010.06.010_bb0045","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1056\/NEJM200109273451312","article-title":"Trastuzumab and breast cancer","volume":"345","author":"Behr","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nucmedbio.2010.06.010_bb0050","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.2967\/jnumed.109.062224","article-title":"111In-DTPA-pertuzumab sensitively detects trastuzumab-mediated HER2 downregulation and tumor response in athymic mice bearing human breast cancer xenografts","volume":"50","author":"McLarty","year":"2009","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2010.06.010_bb0055","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s00259-008-0923-x","article-title":"Associations between the uptake of 111In-DTPA-trastuzumab, HER2 density and response to trastuzumab (Herceptin) in athymic mice bearing subcutaneous human tumour xenografts","volume":"36","author":"McLarty","year":"2009","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.nucmedbio.2010.06.010_bb0060","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1200\/JCO.2005.03.8448","article-title":"Indium-111-labeled trastuzumab scintigraphy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer","volume":"24","author":"Perik","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.nucmedbio.2010.06.010_bb0065","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1038\/nbt968","article-title":"Imaging the pharmacodynamics of HER-2 degradation in response to Hsp90 inhibitors","volume":"22","author":"Smith-Jones","year":"2004","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.nucmedbio.2010.06.010_bb0070","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.nucmedbio.2004.08.003","article-title":"Imaging of HER2\/neu-positive BT-474 human breast cancer xenografts in athymic mice using 111In-trastuzumab (Herceptin) Fab fragments","volume":"32","author":"Tang","year":"2005","journal-title":"Nucl Med Biol"},{"key":"10.1016\/j.nucmedbio.2010.06.010_bb0075","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1097\/00006231-200505000-00006","article-title":"Imaging of HER2\/neu expression in BT-474 human breast cancer xenografts in athymic mice using [99mTc]-HYNIC-trastuzumab (Herceptin) Fab fragments","volume":"26","author":"Tang","year":"2005","journal-title":"Nucl Med Commun"},{"key":"10.1016\/j.nucmedbio.2010.06.010_bb0080","first-page":"485","article-title":"Increased affinity leads to improved selective tumour delivery of single-chain Fv antibodies","volume":"58","author":"Adams","year":"1998","journal-title":"Cancer Res"},{"key":"10.1016\/j.nucmedbio.2010.06.010_bb0085","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1158\/0008-5472.CAN-04-2008","article-title":"Quantitative immuno-positron emission tomography imaging of HER2-positive tumor xenografts with an iodine-124 labeled anti-HER2 diabody","volume":"65","author":"Robinson","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.nucmedbio.2010.06.010_bb0090","doi-asserted-by":"crossref","first-page":"5907","DOI":"10.1158\/0008-5472.CAN-04-4472","article-title":"Optimizing radiolabeled engineered anti-p185HER2 antibody fragments for in vivo imaging","volume":"65","author":"Olafsen","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.nucmedbio.2010.06.010_bb0095","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.2174\/138161208786404290","article-title":"Imaging of HER-2 overexpression in tumors for guiding therapy","volume":"14","author":"Tolmachev","year":"2008","journal-title":"Curr Pharm Design"},{"key":"10.1016\/j.nucmedbio.2010.06.010_bb0100","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.2967\/jnumed.108.057695","article-title":"HER2 expression changes in breast cancer xenografts following therapeutic intervention can be quantified using PET imaging and 18F-labeled affibody molecules","volume":"50","author":"Kramer-Marek","year":"2009","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2010.06.010_bb0105","doi-asserted-by":"crossref","first-page":"417","DOI":"10.2967\/jnumed.108.057919","article-title":"On the selection of a tracer for PET imaging of HER2-expressing tumors: direct comparison of a 124I-labeled affibody molecule and trastuzumab in a murine xenograft model","volume":"50","author":"Orlova","year":"2009","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2010.06.010_bb0110","doi-asserted-by":"crossref","first-page":"126","DOI":"10.2165\/00003088-199528020-00004","article-title":"Problems of delivery of monoclonal antibodies. Pharmaceutical and pharmacokinetic solutions","volume":"28","author":"Reilly","year":"1995","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.nucmedbio.2010.06.010_bb0115","first-page":"701","article-title":"A kit formulated under good manufacturing practices for labeling human epidermal growth factor with 111In for radiotherapeutic applications","volume":"45","author":"Reilly","year":"2004","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2010.06.010_bb0120","series-title":"Octreoscan Kit for the preparation of indium-111 pentetreotide","author":"Anonymous","year":"1995"},{"key":"10.1016\/j.nucmedbio.2010.06.010_bb0125","author":"Anonymous"},{"key":"10.1016\/j.nucmedbio.2010.06.010_bb0130","series-title":"Handbook of Biopharmaceutical Technology","first-page":"987","article-title":"The radiopharmaceutical science of monoclonal antibodies and peptides for imaging and targeted in situ radiotherapy of malignancies","author":"Reilly","year":"2007"}],"container-title":["Nuclear Medicine and Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969805110003239?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969805110003239?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,3]],"date-time":"2019-06-03T05:51:31Z","timestamp":1559541091000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0969805110003239"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,1]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,1]]}},"alternative-id":["S0969805110003239"],"URL":"https:\/\/doi.org\/10.1016\/j.nucmedbio.2010.06.010","relation":{},"ISSN":["0969-8051"],"issn-type":[{"value":"0969-8051","type":"print"}],"subject":[],"published":{"date-parts":[[2011,1]]}}}